Breast cancer

Sonia Pernas Simón / Ruth Rodriguez Barrueco

PRINCIPAL INVESTIGATORS
  • Amparo García Tejedor
CLINICAL RESEARCHERS
  • Silvia Vázquez Fernández
  • Agostina Stradella Trucco
  • Veronica Luisa Obadia Gil
  • Juan Miguel Gil Gil
  • Catalina Falo Zamora
  • Rafael Villanueva Vázquez
  • Adela Fernández Ortega
  • Bartomeu Fullana Grimalt
  • Sabela Recalde Penabad
  • Anna Petit Montserrat
  • María Jesús Pla Farnós
POSTDOCTORAL RESEARCHERS
  • Leticia Manen Freixa
  • Francesca Mateo Gonzalez
PREDOCTORAL RESEARCHERS
  • Luis Alfaro Garcia
  • Julia Migo Aran
  • Ricard Bonilla Amadeo
  • Aintzane Rodriguez Barrante
SCIENTIFIC SUPPORT
  • Santiago Santos Gil
  • Miguel Angel Pardo Cea
Cancer
Oncobell

Scientific production

34

PAPERS

Average IF: 11,63

15

LED PAPERS

Average IF: 3,67

13 PUBLICATIONS IN FIRST DECILE

24 PUBLICATIONS IN FIRST QUARTILE

28 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Pérez García,JM;Cortés,J;Ruiz Borrego,M;Colleoni,M;Stradella,A;Bermejo,B;Dalenc,F et al, 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial, Lancet, 2024;403(10437):1649-1659, doi:10.1016/S0140-6736(24)00054-0
  • Bardia,A;Jhaveri,K;Im,SA;Pernas,S;De Laurentiis,M;Wang,S;Martínez Jañez,N et al, Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01., J. Clin. Oncol., 2024;43(3):285-296, doi:10.1200/JCO.24.00920
  • Turner,N;Saura,C;Aftimos,P;van den Tweel,E;Oesterholt,M;Koper,N;Colleoni,M et al, Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)., J. Clin. Oncol., 2024;doi:10.1200/JCO.24.00529
  • Rivero Santana,B;Saldaña García,J;Caro Codón,J;Zamora,P;Moliner,P;Monzonis,AM;Zatarain,E et al, Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score, Eur. Heart J., 2024;doi:10.1093/eurheartj/ehae496
  • Brasó Maristany,F;Ferrero Cafiero,JM;Falato,C;Martínez Sáez,O;Cejalvo,JM;Margeli,M;Tolosa,P et al, Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response, Nat Commun, 2024;15(1):5826-5826, doi:10.1038/s41467-024-50056-y

Research highlights

PROJECTS

2 Granted competitive projects
2 Ongoing competitive projects
14 Started clinical trials
48 Ongoing clinical trials
1 Ongoing competitive project

INNOVATION

1 Patent

PUBLISHED WORKS

1 Clinical Guideline
1 Thesis

NETWORKS

CIMBA
ENBDC
AGAUR SGR 2017-449
LOBSTERPOT
Immuno-Model COST Action

Selected projects

  • 2023-505928-59-00. A PHASE III, OPEN-LABEL, RANDOMISED STUDY OF NEOADJUVANT DATOPOTAMAB DERUXTECAN (DATO-DXD) PLUS DURVALUMAB FOLLOWED BY ADJUVANT DURVALUMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY FOLLOWED BY ADJUVANT PEMBROLIZUMAB WITH OR WITHOUT CHEMOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED TRIPLE-NEGATIVE OR HORMONE RECEPTOR-LOW/HER2-NEGATIVE BREAST CANCER (D926QC00001; TROPION-BREAST04). AstraZeneca AB. Budget: 323.017,8€. 2024- . PI: Stradella Trucco, Agostina.
  • 2023-506717-21. Ensayo de fase I/II, multicéntrico y abierto de [177Lu]Lu-NeoB en combinación con capecitabina en pacientes adultos con cáncer de mama metastásico receptor del péptido liberador de gastrina positivo, receptor de estrógenos positivo y receptor 2 del factor de crecimiento epidérmico humano negativo después de la progresión con la terapia endocrina previa en combinación con un inhibidor de CDK4/6.. NOVARTIS PHARMA AG.. Budget: 315.654,44€. 2024- . PI: Villanueva Vázquez, Rafael.
  • 2022-502465-18-00. Estudio de fase Ib de búsqueda de dosis en el que se evalúan la seguridad y la actividad de [177Lu]Lu-NeoB en combinación con ribociclib y fulvestrant en participantes con cáncer de mama RE positivo, HER2 negativo y GRPR positivo que hayan presentado una recaída temprana con la terapia endocrina (neo)adyuvante. Novartis Farmaceutica S.A.. Budget: 277.232€. 2023- . PI: Villanueva Vázquez, Rafael.
  • 2022-502145-10-00. A PHASE 3, OPEN-LABEL, RANDOMIZED, TWO-PART STUDY COMPARING GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AND FULVESTRANT TO STANDARD-OF-CARE THERAPIES IN PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER PREVIOUSLY TREATED WITH A CDK4/6 INHIBITOR IN COMBINATION WITH NON-STEROIDAL AROMATASE INHIBITOR THERAPY (VIKTORIA-1). CELCUITY INC. Budget: 253918€. 2023-2999. PI: Stradella Trucco, Agostina.
  • PI24/01014. Impacto sobre el dolor pélvico y la Calidad de Vida de la Punción-Esclerosis con Alcohol vs. Manejo expectante en Pacientes con Endometriomas (Estudio ESCOMA). Instituto de Salud Carlos III (ISCIII). Budget: 152.500€. 2025-2027. PI: García Tejedor, Amparo.